CA2876284A1 - Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis - Google Patents

Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis Download PDF

Info

Publication number
CA2876284A1
CA2876284A1 CA2876284A CA2876284A CA2876284A1 CA 2876284 A1 CA2876284 A1 CA 2876284A1 CA 2876284 A CA2876284 A CA 2876284A CA 2876284 A CA2876284 A CA 2876284A CA 2876284 A1 CA2876284 A1 CA 2876284A1
Authority
CA
Canada
Prior art keywords
nogo
antibody
localisation
days
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2876284A
Other languages
English (en)
French (fr)
Inventor
Jonathan BULLMAN
David KRULL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2876284A1 publication Critical patent/CA2876284A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2876284A 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis Abandoned CA2876284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668134P 2012-07-05 2012-07-05
US61/668,134 2012-07-05
PCT/EP2013/064063 WO2014006105A1 (en) 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CA2876284A1 true CA2876284A1 (en) 2014-01-09

Family

ID=48741180

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876284A Abandoned CA2876284A1 (en) 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis

Country Status (10)

Country Link
EP (1) EP2870177A1 (enExample)
JP (1) JP2015521992A (enExample)
KR (1) KR20150036398A (enExample)
CN (1) CN104395343A (enExample)
AU (1) AU2013285493A1 (enExample)
BR (1) BR112014032987A2 (enExample)
CA (1) CA2876284A1 (enExample)
IN (1) IN2014KN02952A (enExample)
RU (1) RU2014150265A (enExample)
WO (1) WO2014006105A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279751B1 (ko) * 2019-06-28 2021-07-21 경북대학교 산학협력단 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법
KR102409771B1 (ko) * 2020-06-17 2022-06-16 경북대학교 산학협력단 Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법
WO2026041734A1 (en) * 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10336350B4 (de) 2003-08-08 2007-10-31 Westfalia Separator Ag Vollmantel-Schneckenzentrifuge, mit Schälscheibe
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
DK1711530T3 (da) 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP5698534B2 (ja) 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US20110268729A1 (en) 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist

Also Published As

Publication number Publication date
RU2014150265A (ru) 2016-08-27
KR20150036398A (ko) 2015-04-07
IN2014KN02952A (enExample) 2015-05-08
BR112014032987A2 (pt) 2017-06-27
JP2015521992A (ja) 2015-08-03
WO2014006105A1 (en) 2014-01-09
EP2870177A1 (en) 2015-05-13
CN104395343A (zh) 2015-03-04
AU2013285493A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
JP5513380B2 (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
ES2498040T3 (es) Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
TWI705824B (zh) 治療阿茲海默症之方法
US7785587B2 (en) Therapeutic methods for muscular or neuromuscular disorders
JP2020518599A (ja) プログラム死受容体１（ｐｄ−１）抗体の安定製剤およびその使用方法
CN114019170A (zh) 用于阿尔茨海默氏病的高剂量治疗
TWI802942B (zh) Pd-l1/lag-3雙特異性抗體製劑及其製備方法和用途
CA2876284A1 (en) Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
JP7558306B2 (ja) 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
US20170233467A1 (en) Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
WO2025096435A1 (en) Treatment of complement-associated renal diseases
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
HK40068762A (en) High dose treatments for alzheimer's disease
HK40035893A (en) Methods of treating alzheimer's disease
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
HK1261507A1 (en) High dose treatments for alzheimer's disease

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20170704